Clinical comparative efficacy and therapeutic strategies for the Hashimoto's thyroiditis: A systematic review and network meta-analysis

• Published in: Heliyon Vol. 10; no. 16; p. e35114
• Main Authors: Luo, Jinli, Zhou, Ling, Sun, Aru, Min, Ye, Lin, Yiqun, Han, Lin
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 30.08.2024; Elsevier
• Subjects: Hashimoto's thyroiditis; Network meta-analysis; Oral medications; TgAb; TPOAb; TPOAb; Network meta-analysis; Oral medications; TgAb; Hashimoto's thyroiditis
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2024.e35114

Vitamin D (VD), selenium preparations (Se), and thyroid hormone replacement therapy are commonly used to treat Hashimoto thyroiditis (HT). Increasing evidence suggests that traditional Chinese medicine (TCM) is an effective therapeutic strategy in the treatment of HT. This study aimed to investigate the efficacy and safety of commonly-used drugs for HT. A literature search was performed using PubMed, Web of Science, Cochrane Library, EMBASE, Chinese China National Knowledge Infrastructure (CNKI), Clinical Trial Registry (Chi CTR), China Science and Technology Journal Database (the VIP), Wanfang Database, and China Chinese Biomedical Database (CBM) from January 1, 2003, to December 31, 2022. The outcomes included TPOAb, TgAb, TSH, FT3, FT4, and adverse events. Our study was registered in PROSPERO (CRD42023449705). Sixty trials and 4719 participants were included, comparing 16 treatments: VD, Se, LT-4, Se + LT-4, HM, placebo + LT-4, HM + LT-4, Se + myolnositol, Se + VD, HM + Se, mannan peptide, LT-4+prednisone, Methimazole, Methimazole + HM, Tapazole + Propranolol, and placebo. We found that Chinese herbal medicine has significant effect vs. LT-4 [MD 0.10, 95 % confidence interval 0.02 to 0.50]) and LT-4+placebo [MD 0.10, 95 % confidence interval 0.01 to 0.77]) in reducing TPOAb. Although receiving LT-4+prednisone was not statistically significant, the treatment ranking showed that this combination therapy had the highest probability of reducing TPOAb levels (72.8 %). In addition, the effect of Se plus LT-4 was not statistically significant; however, the treatment ranking showed that this combination therapy had the highest probability (78.6 %) of reducing TgAb levels, followed by HM (64.0 %). Reports on side effects have mainly focused on the digestive and cardiovascular systems. Our analyses showed that HM alone or in combination with other treatments for patients with HT can improve the side effects of other drugs, enhance efficacy, and maybe the most effective option for treating HT. However, there still need further verified using high-quality evidence. [Display omitted] •Several drugs have limitations as potential treatment options for HT.•Herbs have unique advantages and curative effects for thyroid diseases.•There is still no clear drug to reduce HT antibodies.